Endocrine Abstracts

Introduction

Dyslipidemia is a major cardiovascular risk factor, being its detection and control essential due to risk of serious complications. Numerous trials have demonstrated its relationship with T2D, but it has not been so well studied in T1D.

Objective

To obtain information about relationship between dyslipidemia and T1D and analyze its prevalence and control in a sample of patients.

Material and methods

Retrospective descriptive observational study that analyzes data from 235 patients with DM1 in Endocrinology Consultation at Virgen de la Victoria Hospital in Malaga.

Results

50.6% were women, with a mean age of 34.59 ± 12.6 years; BMI 25.47 ± 4.27 kg/m² and diabetes of 18.09 ± 10.15 years of evolution. From all of them, 93 (39.6%) had dyslipidemia with mean analytical parameters: glycemia 159 ± 74.4 mg/dl, HbA1c 8.6 ± 7.5%, total cholesterol 179.2 ± 7.5 mg/dl, HDL 59.9 ± 36.6 mg/dl, LDL 106.4 ± 76.9 mg/dl, triglycerides 104 ± 216.5 mg/dl. Only 74 (79.6%) received lipid-lowering treatment: 71 (76.3%) statins; 2 (2.2%) statins plus ezetimibe and 1 (1.1%) fenofibrate; with results at 6 months of: CT 163 ± 32 mg/dl, HDL 57 ± 16 mg/dl, LDL 88 ± 24 mg/dl, TG 90 ± 47 mg/dl. From them 17 (22.97%) achieved LDL < 70 mg/dl; 35 (47.29%) presented figures between 70–100 mg/dl and 22 (29.79%) LDL > 100 mg/dl. The sum of patients in treatment with LDL < 100 mg/dl was 52 (70.26%). In addition, they presented a higher percentage of comorbidities compared to non-dyslipidemic patients: hypertension 43 (18.3%) patients with dyslipidemia compared to 6.3% of non-dyslipidemic patients, smoker 29.8% vs 27.5%; taking antiaggregant 19.6% vs 8.5%; and complications: retinopathy 15.3% vs 9.2%; diabetic kidney diseases 13.2% vs 12.7%; neuropathy 3.8% vs 3.5% and a history of CVD 3% vs 0.7%.

Conclusion

There is a significant relationship between dyslipidemia and age, DM1 evolution time and BMI but not HbA1c. Furthermore, it is more frequent in those patients who present other cardiovascular risk factors.